RadNet completes iCAD acquisition via DeepHealth subsidiary; expands AI breast health

RadNet, Inc.

DeepHealth, RadNet's digital health segment, closed acquisition of iCAD (NASDAQ: ICAD).
iCAD's AI portfolio includes breast cancer detection, risk evaluation, and density assessment in 50+ countries.
Combined installed base of 1,500+ healthcare provider locations, covering over 10 million mammograms annually.
Acquisition positions DeepHealth with industry-leading AI-powered breast cancer screening and workflow solutions.
iCAD will operate as a wholly-owned subsidiary of RadNet, integrated into DeepHealth.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.